GMP News and Research

RSS

H.E.L Group extends sales and support with appointment of specialist distributors

H.E.L Group (H.E.L), a global developer and manufacturer of innovative laboratory tools for process optimization, safety, and scale-up, today announced the extension of its global sales network with the appointment of two distributors: Paralab and ProAnalytics.

From H.E.L Group 31 May 2024

Cellular Origins and Cell and Gene Therapy Catapult collaborate to demonstrate universal automation of CGT manufacturing

Cellular Origins, a TTP Company focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies (CGTs), and the Cell and Gene Therapy Catapult (CGT Catapult), an independent innovation and technology organisation specializing in the advancement of the cell and gene therapy industry, today announced a collaboration to demonstrate universal automation of CGT manufacturing.

29 May 2024

ArgusEye closes €2.8 million funding to accelerate bioprocessing

ArgusEye, a provider of innovative sensor solutions for real-time monitoring of biological systems, today announced the close of its funding, raising €2.8 million EUR (~£2.4 million GBP) bringing the total raised by the Company to €3.45 million EUR (~£3 million GPB).

From ArgusEye AB 13 May 2024

New collaboration to combat river blindness and lymphatic filariasis

Prof. Achim Hoerauf, Director of the Institute of Medical Microbiology, Immunology and Parasitology at the University Hospital Bonn (UKB), and his team have succeeded in collaborating with the Department of Pharmaceutical Technology and Biopharmacy at the University of Bonn and the Helmholtz Center for Infection Research (HZI), to enter into a partnership with the Japanese pharmaceutical company Eisai for the further development of the antibiotic corallopyronin A (CorA) as a treatment for the neglected tropical diseases river blindness and lymphatic filariasis and to raise a large amount of funding.

10 May 2024

Lab to plant: Scaling up API processes with Dr. James Mencel's guidance

In this interview, NewsMed talks to Dr. James Mencel's Guidance about Scaling Up API Processes.

From DSI, a PLG Company 6 May 2024

Asimov achieves 10x improvement in lentiviral production, launches new stable cell line development service

...

30 Apr 2024

Merck introduces Aptegra CHO genetic stability assay for accelerated biosafety testing

Merck, a leading science and technology company, has launched the first all-in-one, validated genetic stability assay of its kind.

23 Apr 2024

Columbia researchers secure $38.95 million ARPA-H contract to build a living knee replacement

A team of researchers from Columbia University Irving Medical Center and Columbia Engineering has been awarded up to a $38.95 million contract from the Advanced Research Projects Agency for Health (ARPA-H) to build a living knee replacement from biomaterials and human stem cells, including a patient's own cells.

26 Mar 2024

EPFL scientists uncover protein degradation mechanism preventing autoimmune reactions

Scientists at EPFL uncover the mechanism by which cells mark the protein cGAS for degradation, which is critical in preventing the immune system from mistakenly attacking the body's own tissues.

28 Feb 2024

Global health boost as new vaccine SKYTyphoid gains WHO prequalification

SK bioscience and the International Vaccine Institute (IVI) announced today that the typhoid conjugate vaccine developed by SK bioscience with technology transfer from IVI has achieved the World Health Organization prequalification (PQ), which paves the way for public procurement of the vaccine by UN organizations and gives a boost to the global TCV supply.

23 Feb 2024

Nose cartilage-based knee joint treatment project receives €2.3 million funding

Treating knee joint defects with cartilage from the nose: The University Hospital in Würzburg is working on the approval of this procedure.

21 Feb 2024

Revvity showcases cutting-edge solutions at SLAS2024

Revvity presents its continued commitment to expanding the boundaries of human potential through science.

From Revvity 5 Feb 2024

Asimov launches LV Edge Packaging System to optimize lentivirus production

New off-the-shelf system reduces the cost and risk of lentiviral (LV) production for cell and gene therapy developers.

From Asimov 29 Jan 2024

New drug combination could reduce malaria infection risk in pregnant women living with HIV

Researchers have tested a new combination of medications that could thwart resistance to common malaria drugs, significantly reducing the infection risk in pregnant women living with HIV.

24 Jan 2024

Core Biogenesis and Nucleus Biologics announce strategic collaboration for manufacturing and distribution of cost effective and sustainable recombinant proteins

In a joint effort to provide lower cost and more defined reagents and media to the cell and gene therapy market, Nucleus Biologics, The Cell Performance Company™, a leading provider of custom cell culture media solutions for the cell and gene therapy industry, has signed a manufacturing, distribution, and collaboration agreement with Core Biogenesis, an innovator in the field of recombinant human proteins expressed in plants.

From Nucleus Biologics 24 Jan 2024

Pangolins' genetic makeup linked to increased coronavirus susceptibility

Research reveals pangolins' vulnerability to coronavirus due to innate immune gene pseudogenization, impacting their antiviral response.

10 Jan 2024

Marking a vital milestone for Vertex and Charles River

Charles River’s Memphis facility approved to manufacture Vertex’s CASGEVY™ therapy, the world’s first gene-edited therapy targeting severe sickle cell disease

From Charles River 9 Jan 2024

Poop-based test predicts postoperative infections in liver transplant patients

In a new study, researchers at the University of Chicago were able to predict postoperative infections in liver transplant patients by analyzing molecules in their poop.

15 Dec 2023

Association of genetically proxied PDE5 inhibition with measures of fertility, sexual behavior, and wellbeing

Researchers performed a two-sample Mendelian randomization analysis to investigate the associations between genetically proxied suppression of PDE5, a recognized pharmacological target for erectile dysfunction, fertility, subjective wellness, and sexual behavior.

14 Dec 2023

Double punch for B-cell lymphomas: CAR T-cell innovation boosts efficacy, cuts toxicity

The Malaghan Institute of Medical Research in collaboration with Wellington Zhaotai Therapies Limited today announced results of its phase 1 dose escalation trial of a new third-generation anti-CD19 chimeric antigen receptor (CAR) T-cell therapy to be presented at the American Society of Hematology (ASH) Annual Meeting in San Diego on 11 December, 3pm.

11 Dec 2023